MDNC · Medinotec Inc.
Market Cap
$58.78M
Shares
11.76M
Volume · Apr 14
100
Avg daily vol (1 sessions)
100
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.00
Open$5.00
Day$5.00–5.00
Available close range$5.00–5.00
Avg vol available · 2d100
Short vol100%
DataJul 2023–Apr 2025
Filing10-Q · Oct 8
The closing range uses available history since Apr 14, 2025; less than a full year is stored.
Up next
filed Oct 8, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$10.21M
Trailing 12 months
Net income (TTM)
$597,032
Trailing 12 months
Revenue growth YoY
-1.1%
Year over year
Operating margin
6.6%
Trailing 12 months
P / E (TTM)
98.4
Trailing earnings · reciprocal yield 1.0%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$2.58M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Limited
Momentum
Limited
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Limited
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
Not enough data for a confident read.
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Revenue growth
+7%
Y/Y
Gross margin
53%
contracting
Free cash flow
$905.4K
Quant / Vol
risk profile
Not enough data for a confident read.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Price range unavailable — no recent comparable closes.
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Distribution-agreement sales outside the U.S. | $2,754,176 | the three months ended August 31, 2026 filing | — |
| Inside the United States of America cost of sales composition | 3% | the three months ended August 31, 2026 filing | — |
| Internally designed and manufactured sales inside the U.S. | $200,122 | the three months ended August 31, 2026 filing | — |
| Internally designed and manufactured sales outside the U.S. | $246,305 | the three months ended August 31, 2026 filing | — |
| Outside United States of America cost of sales composition | 97% | the three months ended August 31, 2026 filing | — |
| Compliance cost | $362,172 | fiscal 2026 filing | -31.2% |
|
|
|||
| Customer concentration - DISA Life Sciences percentage of consolidated revenue | 89% | fiscal year ended February 28, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDNC
this stock
Medinotec Inc.
|
$58.78M | — | +6.8% | — | — |
|
ABT
Abbott Laboratories
|
$180.99B | -16.9% | +5.7% | 33.6 | 0.8% |
|
MDT
Medtronic plc
|
$118.67B | -3.4% | +8.4% | 22.9 | 3.1% |
|
SYK
Stryker Corp
|
$114.28B | -15.2% | +11.2% | 30.9 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.16B | -52.8% | +12.5% | 18.2 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDNC | — | — | — | +0.0% | +0.0% |
| SPY | +6.9% | -4.9% | -7.8% | -3.6% | -8.0% |
| vs SPY | — | — | — | +3.6% | +8.0% |